Fresenius Reaffirms 2026 Outlook

Bitget2026/11/02 06:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Fresenius maintained its full-year 2026 outlook.
Biopharma revenue is targeted to nearly double by 2030 from 2025, with an EBIT margin of around 20%.
The company expects to significantly raise its longer-term Biopharma ambitions following an exclusive development agreement with WuXi Biologics.
The agreement provides access to up to 37 biosimilar candidates, potentially expanding the portfolio from 29 to 66 molecules over a decade.
Rising development spending will weigh on profitability before products contribute growth; operating cash flow will fund the agreement without additional debt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2426078_de) on November 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Fresenius Reaffirms 2026 Outlook

You may also like

Crypto prices